T. Rowe Price Associates’s Acceleron Pharma XLRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
|
|||||
|
2021
Q3 | $923M | Buy |
|
|||||
|
2021
Q2 | $665M | Sell |
|
|||||
|
2021
Q1 | $727M | Buy |
|
|||||
|
2020
Q4 | $679M | Buy |
|
|||||
|
2020
Q3 | $585M | Buy |
|
|||||
|
2020
Q2 | $448M | Buy |
|
|||||
|
2020
Q1 | $365M | Buy |
|
|||||
|
2019
Q4 | $182M | Buy |
|
|||||
|
2019
Q3 | $135M | Sell |
|
|||||
|
2019
Q2 | $155M | Sell |
|
|||||
|
2019
Q1 | $209M | Sell |
|
|||||
|
2018
Q4 | $218M | Buy |
|
|||||
|
2018
Q3 | $272M | Buy |
|
|||||
|
2018
Q2 | $208M | Buy |
|
|||||
|
2018
Q1 | $142M | Buy |
|
|||||
|
2017
Q4 | $135M | Buy |
|
|||||
|
2017
Q3 | $118M | Sell |
|
|||||
|
2017
Q2 | $117M | Sell |
|
|||||
|
2017
Q1 | $103M | Buy |
|
|||||
|
2016
Q4 | $94.9M | Buy |
|
|||||
|
2016
Q3 | $119M | Buy |
|
|||||
|
2016
Q2 | $107M | Buy |
|
|||||
|
2016
Q1 | $77.8M | Buy |
|
|||||
|
2015
Q4 | $143M | Sell |
|
|||||
|
2015
Q3 | $77.8M | Sell |
|
|||||
|
2015
Q2 | $99.6M | Sell |
|
|||||
|
2015
Q1 | $121M | Sell |
|
|||||
|
2014
Q4 | $133M | Buy |
|
|||||
|
2014
Q3 | $97.8M | Sell |
|
|||||
|
2014
Q2 | $111M | Buy |
|
|||||
|
2014
Q1 | $63.6M | Buy |
|
|||||
|
2013
Q4 | $19.2M | Buy |
|